Rigel(US:RIGL) Seeking Alpha·2026-01-01 09:41Core Insights - The article discusses the author's long-term positive outlook on Rigel Pharmaceuticals (RIGL), particularly highlighting the potential of its drug TAVALISSE and the company's promising pipeline [1]. Company Overview - Rigel Pharmaceuticals has been under observation for seven years, with a focus on its innovative therapies and potential for growth in the biotech sector [1]. - The company is noted for developing breakthrough therapies and pharmaceuticals that may attract acquisition interest [1]. Investment Strategy - The author emphasizes a strategy centered around identifying innovative companies in the healthcare sector that are developing life-saving therapies [1]. - The investment group, Compounding Healthcare, offers various resources including model healthcare portfolios, newsletters, and a watchlist for potential investment opportunities [1].